EA
GILD icon

Ellsworth Advisors’s Gilead Sciences GILD Stock Holding History

Ellsworth Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,512
Closed -$933K – 185
2023
Q4 		$933K Buy
11,512
+1,170
+11% +$91K 0.3% 78
2023
Q3 		$811K Buy
10,342
+3,470
+50% +$267K 0.29% 75
2023
Q2 		$530K Buy
6,872
+310
+5% +$24.7K 0.18% 96
2023
Q1 		$544K Buy
6,562
+1,075
+20% +$89K 0.19% 83
2022
Q4 		$460K Buy
5,487
+1,316
+32% +$104K 0.17% 91
2022
Q3 		$257K Buy
4,171
+464
+13% +$29.3K 0.11% 124
2022
Q2 		$229K Buy
+3,707
New +$230K 0.09% 128

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ellsworth Advisors's GILD Position: Q1 2024 in Review

Ellsworth Advisors sold out of Gilead Sciences (GILD) in Q1 2024, closing a stake of 11,512 shares — an estimated $933K sold.

Ellsworth Advisors first reported a position in GILD in Q2 2022 and held it in 7 quarters. The position peaked at $933K in Q4 2023. 1,721 funds tracked by Wall St. Rank hold GILD as of Q1 2024.

  • Ellsworth Advisors reported no remaining Gilead Sciences position as of Q1 2024 after selling out during the quarter.
  • Ellsworth Advisors sold 11,512 Gilead Sciences shares in Q1 2024, an estimated $933K.
  • Ellsworth Advisors first reported a position in Gilead Sciences in Q2 2022 and held it in 7 quarters.
  • Ellsworth Advisors's Gilead Sciences position peaked at $933K in Q4 2023.
  • 1,721 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.

Based on Ellsworth Advisors's 13F filing for Q1 2024, filed 15 Apr 2024.